Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: Insights from ROCKET AF

European Heart Journal

Volumn 35, Issue 4, 2014, Pages 242-249

  Jones, William Schuyler ^a   Hellkamp, Anne S ^a   Halperin, Jonathan ^b   Piccini, Jonathan P ^a   Breithardt, Gunter ^c   Singer, Daniel E ^d   Fox, Keith A A ^e   Hankey, Graeme J ^f   Mahaffey, Kenneth W ^a   Califf, Robert M ^a   Patel, Manesh R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Atrial fibrillation; Bleeding; Peripheral artery disease; Rivaroxaban; Stroke; Systemic embolism

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON VALVULAR ATRIAL FIBRILLATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSIENT ISCHEMIC ATTACK;

ATRIAL FIBRILLATION; BLEEDING; PERIPHERAL ARTERY DISEASE; RIVAROXABAN; STROKE; SYSTEMIC EMBOLISM;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; EMBOLISM; FEMALE; HUMANS; MALE; MORPHOLINES; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84893153218     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht492     Document Type: Article

References (12)

1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 2010; 137:263-272.
2. Aguilar E, Garcia-Diaz AM, Sanchez Munoz-Torrero JF, Alvarez LR, Piedecausa M, Arnedo G, Monreal M. Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation. Thromb Res 2012;130: 390-395.
3. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D'Agostino R, Ohman EM, Liau CS, Hirsch AT, Mas JL, WilsonPW, Corbalán R, Aichner F, Steg PG. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-863.
4. WinkelTA, Hoeks SE, Schouten O, Zeymer U, Limbourg T, Baumgartner I, Bhatt DL, Steg PG, Goto S, Röther J, Cacoub PP, Verhagen HJ, Bax JJ, Poldermans D. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: Datafrom the REduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg 2010;40:9-16.
5. Olesen JB, Lip GY, Lane DA, Kober L, Hansen ML, Karasoy D, Hansen CM, Gislason GH, Torp-Pedersen C. Vascular disease and stroke risk in atrial fibrillation: A nationwide cohort study. Am J Med 2012;125:826 e13-23.
6. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;58: 2020-2045.
7. Collaborative meta-Analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: 71-86.
8. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-Analysis of randomized trials. JAMA 2009;301:1909-1919.
9. Gage BF, vanWalraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-2292.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
11. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin Kantagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-347.
12. Rasmussen LH, Larsen TB, Due KM, Tjonneland A, Overvad K, Lip GY. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: The Danish Diet, Cancer and Health Cohort Study. J Thromb Haemost 2011;9: 1301-1307.